mRNA Cancer Vaccines: Melanoma Phase 3 Trials

The medical community is currently witnessing a pivotal shift in oncology as the technology used to fight COVID-19 is repurposed to battle cancer. Moderna and Merck are currently recruiting for a massive Phase 3 clinical trial involving a personalized mRNA vaccine. This experimental treatment is designed to train the immune system to recognize and destroy specific cancer cells in patients with high-risk melanoma.

The INTerpath-001 Trial Explained

The collaboration between Moderna and Merck represents one of the most significant efforts to date in the field of cancer immunotherapy. The trial, officially known as INTerpath-001, is testing a combination therapy for patients who have had their melanoma surgically removed but remain at high risk of the cancer returning.

The treatment regimen involves two specific drugs:

  1. V940 (mRNA-4157): This is Moderna’s investigational personalized mRNA cancer vaccine.
  2. Keytruda (pembrolizumab): This is Merck’s standard-of-care anti-PD-1 therapy, known as a checkpoint inhibitor.

The goal of this Phase 3 study is to determine if receiving the vaccine alongside Keytruda is more effective than receiving Keytruda alone. The trial aims to recruit approximately 1,089 patients globally. Participants must have resected Stage IIB through Stage IV cutaneous melanoma.

How the Personalized Vaccine Works

Unlike a flu shot that is identical for everyone, the V940 vaccine is custom-made for every single patient. The process involves a highly sophisticated chain of medical logistics:

  • Sample Collection: Doctors take a sample of the patient’s tumor and a sample of their healthy blood.
  • Genetic Sequencing: These samples are sent to a lab where the DNA sequence of the tumor is compared against the healthy blood. This helps identify unique mutations, known as neoantigens, which are present only on the cancer cells.
  • Selection and Manufacturing: Using advanced algorithms, scientists select up to 34 specific neoantigens that are most likely to trigger a strong immune response. A specific mRNA sequence is then manufactured to encode for these mutations.
  • Administration: When injected, the mRNA instructs the patient’s cells to produce these specific protein fragments. This acts as a “Wanted” poster, teaching the immune system exactly what the remaining cancer cells look like so T-cells can hunt them down.

Promising Data from Phase 2b

The optimism surrounding this Phase 3 trial is grounded in concrete data from the previous Phase 2b study (KEYNOTE-942). The results, which followed patients for approximately three years, showed a statistically significant improvement in patient outcomes.

Patients who received the combination of the mRNA vaccine and Keytruda experienced a 44% reduction in the risk of recurrence or death compared to those who only received Keytruda. Furthermore, the data showed a 49% reduction in the risk of distant metastasis (cancer spreading to other parts of the body) or death.

These numbers are substantial because Keytruda is already a highly effective drug. Improving upon the current gold standard by nearly 50% suggests that the vaccine adds a powerful new layer of protection.

Why Combine It with Keytruda?

You might wonder why the vaccine isn’t just given alone. The answer lies in how cancer evades detection. Cancer cells often use a “brake” on the immune system to stop T-cells from attacking them. Keytruda works by releasing this brake (blocking the PD-1 pathway).

However, releasing the brake only works if the immune system knows what to attack. The mRNA vaccine provides the steering. It shows the immune system the specific target (the neoantigens). By combining the two, doctors hope to release the brakes and steer the immune system directly toward the cancer.

Global Recruitment and Early Patients

The trial is currently active in multiple countries, including the United States, Australia, and the United Kingdom.

In the UK, the first patients began receiving treatments in early 2024. University College London Hospitals (UCLH) has been a focal point for this rollout. One of the first British participants, Steve Young, a 52-year-old from Hertfordshire, made headlines when he received his personalized injection. He had a melanoma removed from his scalp and joined the trial to prevent recurrence.

These early participants are critical. They commit to a year of treatment, receiving the vaccine every three weeks for a total of nine doses, alongside the standard Keytruda infusions which occur every three weeks for about a year.

Side Effects and Safety Profile

One of the benefits of mRNA technology, as observed during the COVID-19 pandemic, is a generally manageable safety profile compared to traditional chemotherapy.

In the Phase 2b trials, the adverse effects were consistent with what doctors usually see with immunotherapy. Common side effects reported included:

  • Fatigue
  • Pain at the injection site
  • Chills
  • Headache

While serious immune-related adverse events can happen with Keytruda, the addition of the mRNA vaccine did not significantly increase the rate of severe side effects in the earlier trials. This suggests that the body tolerates the additional instruction from the mRNA well.

Regulatory Status and Future Timeline

Recognizing the potential of this treatment, regulatory bodies have moved to expedite the review process. The U.S. Food and Drug Administration (FDA) granted V940/mRNA-4157 Breakthrough Therapy Designation. Similarly, the European Medicines Agency (EMA) granted it access to the PRIME scheme.

These designations are reserved for drugs that demonstrate substantial improvement over available therapies. They allow for faster development and review timelines.

While the Phase 3 trial is ongoing, primary completion is estimated for roughly 2029, though interim results could be released much sooner if the data is overwhelmingly positive. If the trial succeeds, this could become the first approved mRNA cancer vaccine, potentially opening the door for similar vaccines treating lung cancer, bladder cancer, and other solid tumors.

Frequently Asked Questions

Is this vaccine available to the public now? No. The Moderna-Merck melanoma vaccine is currently only available to patients participating in the INTerpath-001 clinical trial. It has not yet been approved for general commercial use by the FDA or other regulatory agencies.

Does this vaccine cure existing cancer? This specific trial focuses on adjuvant therapy. This means it is used after surgery to kill any microscopic cancer cells left behind and prevent the cancer from coming back. It is currently being tested as a preventative measure against recurrence rather than a cure for large, existing tumors.

How is this different from the COVID-19 vaccine? While the delivery vehicle (mRNA) is the same technology, the content is different. The COVID-19 vaccine codes for the spike protein of a virus. This cancer vaccine codes for unique mutations found specifically in your own tumor. It is strictly personalized medicine; your vaccine cannot be used by anyone else.

Who is eligible for the trial? Eligibility is strict. You generally must have resected Stage IIB, IIC, III, or IV cutaneous melanoma. You cannot have received prior systemic therapy for your melanoma. Patients interested in the trial should consult their oncologist immediately, as enrollment windows and locations change frequently.